| P2093 | author name string | Todd A. Linsenmeyer | |
| P2860 | cites work | Neurourology and Urodynamics | Q15753354 |
| | Botulinal neurotoxins: revival of an old killer | Q23832313 |
| | Anticholinergic drugs versus placebo for overactive bladder syndrome in adults | Q24243870 |
| | Potentiation of neuromuscular weakness in infant botulism by aminoglycosides | Q28328345 |
| | Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence | Q34089190 |
| | Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskra | Q34198222 |
| | Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). | Q34202884 |
| | The impact of spinal cord injury on sexual function: concerns of the general population | Q34573151 |
| | Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies | Q34667968 |
| | Drug Insight: biological effects of botulinum toxin A in the lower urinary tract | Q35057523 |
| | Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. | Q35068975 |
| | Molecular composition of Clostridium botulinum type A progenitor toxins | Q35488061 |
| | Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. | Q35941627 |
| | Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc | Q36370617 |
| | Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder | Q81018432 |
| | Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections | Q81096770 |
| | Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity | Q81330318 |
| | Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre | Q81471456 |
| | Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 |
| | Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions | Q82406015 |
| | Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients | Q82588707 |
| | Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A | Q82729793 |
| | Terminology for preparations of botulinum neurotoxins: what a difference a name makes | Q83129148 |
| | Botulinum toxin: does the black box warning justify change in practice? | Q83228674 |
| | Botulinum toxin injection: a review of injection principles and protocols | Q36815354 |
| | Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. | Q36995681 |
| | Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? | Q37483439 |
| | Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery | Q37538596 |
| | Botulinum Toxin Therapy for Neurogenic Detrusor Overactivity | Q37801072 |
| | Botulinum toxin type A for the treatment of lower urinary tract disorders | Q37973408 |
| | Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury | Q40002317 |
| | Review lecture. Neurotransmitters and trophic factors in the autonomic nervous system | Q40085104 |
| | Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. | Q40171184 |
| | Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. | Q40450175 |
| | Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. | Q42607585 |
| | Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder | Q43203907 |
| | Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. | Q43762643 |
| | Clostridium botulinum and botulinum neurotoxin | Q45161800 |
| | The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study | Q45269477 |
| | Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | Q46349100 |
| | Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence | Q46434816 |
| | Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database | Q46560975 |
| | Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity | Q46586297 |
| | Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 |
| | European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity | Q47892069 |
| | Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 |
| | Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries | Q48638350 |
| | Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. | Q49073287 |
| | Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. | Q51458905 |
| | Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. | Q51761539 |
| | Formation of the neuromuscular junction: molecules and mechanisms. | Q52182201 |
| | In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. | Q52564969 |
| | Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. | Q52923735 |
| | Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. | Q53194715 |
| | The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 |
| | Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre | Q61868320 |
| | Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity | Q62626440 |
| | The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992 | Q68012968 |
| | Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients | Q68331136 |
| | Radioisotope renography in spinal cord injury | Q70052239 |
| | Silent autonomic dysreflexia during voiding in men with spinal cord injuries | Q70892465 |
| | Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction | Q71083309 |
| | Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results | Q74206910 |
| | Acute management of autonomic dysreflexia: individuals with spinal cord injury presenting to health-care facilities | Q74248952 |
| | Other noncosmetic uses of BOTOX | Q74656219 |
| | Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity | Q78462264 |
| | Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity | Q79400222 |
| | Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage | Q79924820 |
| | Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study | Q80973713 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 402-19 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | The journal of spinal cord medicine : JSCM | Q26853939 |
| P1476 | title | Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review | |
| P478 | volume | 36 | |